Inactive Instrument

Press Releases Amryt Pharma plc

Equities

AMYT

US03217L1061

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Chiesi Global Rare Diseases Announces Health Canada Approval of MYALEPTA™ (metreleptin for injection) for the Treatment of Patients with Lipodystrophy	02-05	AQ
Key Senior Members of Former Amryt Pharma Leadership Team join Poolbeg Pharma	11-10	AQ
2022 for Chiesi, The Group's international growth continues	12/04/23	AQ
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc	12/04/23	GL
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc	12/04/23	GL
2022 for Chiesi: The Group’s international growth continues	11/04/23	AQ
Amryt Pharma Plc - High Court of Justice of England and Wales Sanctions Scheme of Arrangement	04/04/23	AQ
High Court of Justice of England and Wales Sanctions Scheme of Arrangement	03/04/23	GL
High Court of Justice of England and Wales Sanctions Scheme of Arrangement	03/04/23	AQ
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici	22/03/23	GL
AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT	24/02/23	BU
AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023	16/02/23	GL
AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023	16/02/23	AQ
AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT	11/01/23	BU
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc	08/01/23	AQ
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc	08/01/23	GL
Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH	05/01/23	GL
COMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors	19/12/22	GL
European Commission approves Mycapssa® for the treatment of Acromegaly	05/12/22	GL
Amryt Announces New Patent for Mycapssa®	30/11/22	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Amryt Pharma plc

Equities

AMYT

US03217L1061

Press Releases

Filters